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Abstract 
Tolerogenic dendritic cells (tolDCs) are a promising therapeutic tool to restore 
immune tolerance in autoimmune diseases. The rationale of using tolDCs is that they 
can specifically target the pathogenic T cell response, while leaving other, protective 
T cell responses intact. Several ways of generating therapeutic tolDCs have been 
described, but whether these tolDCs should be loaded with autoantigen(s), and if so, 
with which autoantigen(s), remains unclear. Autoimmune diseases, such as 
rheumatoid arthritis, are not commonly defined by a single, universal, autoantigen. A 
possible solution is to utilize surrogate autoantigens for loading of tolDCs. We 
propose that heat shock proteins (HSPs) may be a relevant surrogate antigen, as 
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they are evolutionary conserved between species, ubiquitously expressed in inflamed 
tissues and have been shown to induce regulatory T cells, ameliorating disease in 
various arthritis mouse models. In this review, we provide an overview on how 
immune tolerance may be restored by tolDCs, the problem of selecting relevant 
autoantigens for loading of tolDCs, and why HSPs could be used as surrogate 
autoantigens.  
 
1. Restoring immune tolerance to ‘self’ in autoimmune disease: a 
promising clinical intervention 
Immune tolerance is crucial for preventing destructive immune responses to self-
tissues. In healthy individuals, immune tolerance is maintained at different levels: in 
the thymus, where T cells that strongly react to self-antigens are deleted; and in the 
periphery, where self-reactive T cells that escaped negative selection in the thymus 
are kept in check by regulatory cells. A breach in immune tolerance facilitates 
immune attacks on self-tissues that, when becoming dysregulated, lead to chronic 
autoimmune disorders. 
Regulatory T cells (Tregs) play a pivotal role in maintaining immune tolerance in 
the periphery. They are a heterogeneous population of cells that can either be 
derived from the thymus (naturally occurring Tregs) or can be induced in the 
periphery from naïve CD4+ T cells (induced Tregs). They exert their suppressive 
action on immune effector cells through a number of distinct mechanisms, including 
inhibition of antigen-presenting cell function, killing of effector cells, secretion of 
immunosuppressive cytokines and compounds, and interference with metabolic 
pathways (reviewed in 1,2). 
Tregs are critical to preventing autoimmune disease. A total loss of functional 
Tregs, as seen in IPEX (immunodysregulation polyendocrinopathy enteropathy X-
linked syndrome) patients, leads to severe autoimmunity affecting multiple organs 3. 
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In specific autoimmune diseases, however, it is thought that a more subtle change in 
the function of Tregs is involved in the pathogenesis. For example, although type I 
diabetes patients have similar numbers of Tregs as healthy controls, their Tregs 
display reduced suppressive activity and defects in IL-2 signaling 4-6. In rheumatoid 
arthritis (RA) patients, Tregs have reduced ability to suppress inflammatory cytokine 
production 7. Furthermore, enhanced numbers of Tregs co-expressing IL-17 were 
found in both the peripheral blood and synovial fluid of RA patients, suggesting 
conversion of Tregs into inflammatory cytokine-producing effector cells 8. 
Restoration of Treg function is emerging as a promising clinical intervention for 
autoimmune diseases. One way of achieving this is by replenishing the Treg pool in 
autoimmune patients with functional Tregs, either by treating patients with drugs that 
selectively expand Tregs in vivo, or by generating new Tregs ex vivo before injecting 
them into the patient (reviewed in 2,9). However, a downside of this approach is that 
expanding Tregs ‘randomly’ may give rise to general suppression of the immune 
response, thereby increasing the risk of infection, and perhaps even cancer. A 
preferred approach would be to direct the Treg response to defined and relevant 
antigens that are being expressed in the target tissue. This would not only limit off-
target immunosuppression, but would most likely also increase the efficacy of the 
Treg therapy, as was indeed shown in mouse models10,11. An outstanding issue is, 
however, how to achieve the expansion of antigen-specific Tregs, and how to choose 
the relevant antigen(s). Here, we propose to use tolDCs to induce Tregs against 
heat-shock proteins that are ubiquitously expressed in inflamed target tissues, as 
outlined below. 
 
2. Tolerogenic dendritic cells as a therapeutic tool 
DCs are a heterogeneous family of professional antigen presenting cells (APC) that 
can be classified on the basis of their ontogeny, surface marker expression profile 
and their anatomical location (reviewed in 12). DCs are as important for the induction 
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of effective immunity against invading pathogens as they are for the maintenance of 
immune tolerance. Primary immunodeficiency patients with mutations in GATA2 have 
defective DC function, resulting in enhanced susceptibility to infection and cancer, 
but also to autoimmune conditions, most likely due to a reduction in Tregs 13  
The role of DCs in instigating immunity versus tolerance is largely determined 
by their maturation status. Under steady-state conditions, tissue DCs are immature, 
expressing low levels of MHC-II and co-stimulatory molecules; their ‘default’ setting is 
to induce tolerance. These immature DCs can become immunogenic when they 
sense pathogen-associated molecular patterns (PAMPs) and danger-associated 
molecular patterns (DAMPs) via pattern recognition receptors (PRRs). These include 
toll like receptors (TLRs), retinoic-acid-inducible gene I (RIG-I)-like receptors (RLRs), 
and nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs). PRR-
mediated signaling plays a central role in the maturation process that DC need to 
undergo to acquire potent T-cell stimulatory properties 14. Fully matured DCs express 
high levels of MHC-II, co-stimulatory markers (e.g. CD86) and pro-inflammatory 
cytokines (e.g. IL-12p70, IL-23, TNFα), all required for the efficient induction of T 
effector cell responses. Furthermore, during DC maturation the expression of 
chemokine receptors is modulated (e.g. CCR5 is downregulated and CCR7 is 
upregulated) enabling DC migration towards lymphoid tissues to present antigen to 
naive T cells. However, the outcome of maturation of DC is not always the generation 
of DC with immunogenic properties. Certain DAMPs and immune suppressive 
compounds have been shown to drive the maturation of DC with tolerogenic 
properties (tolDC) 15-18. These tolDCs may be phenotypically mature (i.e. high levels 
of MHC II and co-stimulatory molecules), but may express co-inhibitory molecules 
(e.g. PD-L1, PD-L2, ILT3), lack expression of pro-inflammatory cytokines and instead 
produce immunosuppressive cytokines and compounds (e.g. IL-10, TGF-β, IDO). 
The maturation status of these DC has been referred to as ‘semi-mature’. Thus, there 
is plasticity with regard to the functional maturation of DC, and the environmental 
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cues that DC receive during the maturation process determines whether they 
become immunogenic or tolerogenic.  
DCs are able to mediate tolerance via several mechanisms. They can induce 
iTregs through, for example, membrane-bound PD-L1, which blocks the Akt/mTOR 
pathway to preferentially stimulate naive T cells to become iTregs 19.  Furthermore, 
PD-L1 and PD-L2 provide inhibitory signals to both CD8+ and CD4+ T cells which 
drives the T cell into a state of tolerance 19. Secreted compounds such as IL-10, IL-
27, TGF-β, retinoic acid and IDO, can convert naïve T cells into iTregs. DC can also 
promote T cell tolerance through T cell killing, and the induction of T-cell 
hyporesponsiveness (anergy) 20,21. 
 The importance of DC in maintaining immune tolerance has led to exploring 
the therapeutic use of DC. Various ways have been described to create DC with 
stable tolerogenic properties, called tolDCs. The tolerogenic properties of these in 
vitro generated tolDCs depend on the specific method used (reviewed in 22). For 
example, tolDCs generated with the immunosuppressive agents dexamethasone 
and/or the active form of Vitamin D3 (1α,25-Dihydroxyvitamin D3) are characterized 
by a semi-mature phenotype, with high levels of MHC II, intermediate levels of co-
stimulatory molecules, low levels of pro-inflammatory cytokines and high levels of 
immunosuppressive cytokines IL-10 and TGF-β. 23-27. TolDCs can also be genetically 
engineered, for example through the transduction of immunosuppressive or pro-
apoptotic molecules (e.g. IL-10, CTLA-4, FASL) or silencing of immunostimulatory 
molecules (e.g. CD80/CD86, IL-12) (Reviewed in 28). These different types of tolDCs 
have been shown to reduce or prevent autoimmune diseases or transplant rejection 
in animal models, providing important proof of principle evidence that these cells can 
be applied therapeutically 27,29-33. Their therapeutic benefit is associated with a 
reduction of pro-inflammatory effector T cells and NK cells, and the induction of 
regulatory T-cells or IL-10-producing T cells27,29,34-36.  
7 
 
Efforts have been made to translate these findings from animal studies to the 
clinical setting. Good Manufacturing Protocols to generate tolDCs from human donor 
cells have been developed26,37, and methods to preserve the tolDCs and reduce the 
production costs are being explored 29. Since there are diverse methods of 
generating tolDCs and other types of tolerogenic APC (tolAPC), a minimal 
information model for tolAPC (MITAP) was generated. MITAP enables researchers to 
report their data in a standardized and more transparent manner, facilitating data 
comparison and interpretation, ultimately paving the way for the development of 
standardized protocols for the production of tolDCs and other tolAPC for therapeutic 
application 38. A number of tolDCs have been tested in phase I clinical trials, including 
for type I diabetes 30, Crohn’s disease 39 and rheumatoid arthritis 40,41. Encouragingly, 
tolDCs therapy in all these studies was found to be feasible and safe, providing 
rationale to conduct further studies into their efficacy. 
 
3. The problem of targeting autoantigen(s) – which ones? 
One of the main advantages of tolDC therapy is the specific targeting of pathogenic 
immune responses. Many of the drugs that are currently used to treat autoimmune 
diseases are non-antigen specific, leading to general immunosuppression. With 
tolDCs autoreactive T cells can, theoretically, be exclusively targeted. But how to 
achieve this is still a debate. A number of studies have provided clear evidence that 
tolDCs need to be loaded with a disease-relevant antigen to exert their beneficial 
immune modulatory action. Loading of tolDCs with type II collagen was required, for 
example, for antigen-specific disease remission in the collagen-induced arthritis 
model 27,42,43. More recent research shows that this is also applicable in other 
autoimmune diseases 44. Furthermore, when comparing the therapeutic action of 
unloaded tolDCs and tolDCs loaded with a disease relevant peptide (MOG40-55) in the 
experimental autoimmune encephalomyelitis (EAE) model, Mansilla et al showed that 
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although the unloaded tolDCs inhibited disease symptoms, the MOG40-55 loaded 
tolDCs diminished disease even more 45. 
In contrast, other studies have shown that disease remission can be 
established when administering unloaded tolDCs 46,47. This may suggest that tolDCs 
are able to take up the relevant antigen in vivo. It has been hypothesized that 
unloaded tolDCs induce T cell anergy rather than promoting Tregs. These anergic T 
cells might be capable of suppressing excessive Th17 and Th1 responses 48. Non-
antigen-pulsed tolDCs might also induce regulatory populations that do not require 
an antigen. For instance, B cells can be converted into Bregs partly through the 
production of retinoic acid by the tolDC 49. However, if these non-antigen-pulsed 
tolDCs are able to take up antigen in vivo, one has to consider the safety of these 
tolDCs, since it is possible that the non-antigen-pulsed tolDCs also take up other 
antigens that should not be targeted.  
Nonetheless, if tolDCs need to be loaded with antigen(s) prior to infusion, a 
remaining problem is the question of which antigen to use, and in what form. In many 
autoimmune diseases, including RA, the knowledge about the relevant 
autoantigen(s) involved is insufficient. Moreover, even if some of the relevant 
autoantigens are known, as is the case for multiple sclerosis (MS), the problem of 
HLA diversity remains 44. Some peptides (e.g. proteolipid protein) that have been 
shown to be involved in the pathogenesis of MS are restricted to a specific HLA-class 
(e.g. HLA-DQB1*0602), making it more difficult to standardise the peptides used for 
all MS patients 50. 
For RA, no universal autoantigen exists. Several candidate self-proteins have 
been described in relation to the pathogenesis of this disease. Epitopes from joint-
derived antigens such as collagen type II (CII) and human cartilage-derived 
glycoprotein HCgp39 are presented by DCs and macrophages to T cells in inflamed 
joints of RA patients 51. Furthermore, the endoplasmic reticulum (ER) stress-
associated protein GRP78/BiP is described as a potential autoantigen. The ER stress 
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response is increased in RA synovial tissue and fluid and the ER chaperone, GRP78, 
is important for synoviocyte proliferation and angiogenesis, which are substantial 
indicators of RA 52.  
Posttranslational modifications may also be important in generating novel 
epitopes that trigger autoimmunity. Anti-citrullinated peptide antibodies (ACPAs) are 
found in sera of 70-80% of RA patients 53. Immunogenetic studies have shown that 
more than 90% of the RA patients share a HLA-II epitope in the DRB1 chain (HLA-
DRB1 *0101, *0401, *0404). This so-called shared epitope (SE) is also associated 
with ACPAs; SE-positive patients are predisposed to having ACPAs 54,55. Feitsma et 
al identified two HLA-DRB1 restricted CD4+ T cell clones that recognized citrullinated 
vimentin and were also present in the inflamed joint of RA patients. This indicates 
that CD4+ T cells can respond to naturally processed epitopes from an autoantigen 
54. The finding that ACPAs were present in inflamed joints of patients but not in the 
joints of healthy individuals, together with the discovery that citrullinated autoantigen 
specific CD4+ T cells were only found in PBMCs from RA patients, suggests that both 
the ACPAs and these CD4+ T cells play a significant role in the pathogenesis of RA 
55,56. Scally et al (and others) provide molecular evidence on how CD4+ T cells are 
able to recognize citrullinated antigens 57-59. They also showed that in the autoantigen 
recognizing CD4+ T cell population of HLA-DRB1*04:01+ RA patients, the percentage 
Tregs (both activated and resting) was reduced, whereas the populations of naïve 
and effector memory CD4+ T cells were increased compared to healthy subjects 57. 
This indicates that citrullinated peptides are plausible autoantigens in RA. 
To test if citrullinated antigens are good candidates for an immunomodulatory 
therapy, a phase I clinical trial was performed. In this study autologous in vitro 
generated tolDCs were exposed to citrullinated autoantigenic epitopes and 
administered intradermally into patients 40. The trial showed that the DC vaccination 
was safe and indicated an anti-inflammatory effect after DC administration. However, 
using citrullinated peptides has the consequence that therapy is limited to patients 
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with HLA-DRB1 (*0101, *0401, *0404) and it is unknown if the reactivity in these 
patients is similar. We took a different approach in our recent phase I safety trial in 
patients with rheumatoid and inflammatory arthritis 41. TolDCs were loaded with 
autologous synovial fluid; the rationale being that this fluid contains relevant joint-
associated antigens. The downside of this approach is that it is not always possible 
to obtain sufficient synovial fluid from RA patients for tolDC loading. Furthermore, as 
the antigens are unknown, it is difficult to monitor changes in the antigen-specifc T 
cell response after tolDC administration.  
The use of surrogate autoantigens could be a preferred option for the loading 
of tolDCs. Possible candidates are heat shock proteins (HSPs). HSPs are typically 
intracellular proteins, with no peptide leader sequences that can target secretion. 
However, there is evidence that HSP can have access to the extracellular milieu, 
either by passive or active mechanisms. Both the endogenous upregulation of HSP 
with so-called HSP co-inducers and the exogenous administration of (recombinant) 
HSP have led to immunomodulatory effects in various models of experimental 
autoimmunity 60-62. Therefore, HSPs could be used as surrogate autoantigen not only 
for RA but also for other auto-immune diseases. This will be discussed in further 
detail in the next section. 
 
4. HSPs as surrogate autoantigens for autoimmunity 
 
The main function of HSPs is to support folding and transport of a large variety of 
(misfolded) proteins as intracellular molecular chaperones. Their expression can be 
significantly upregulated under conditions of stress like fever, viral infection, 
nutritional deficiency, cold and exposure to the pro-inflammatory cytokines IFN-γ and 
TNF-α 63-65. Generally, HSPs can be classified into different families based on their 
monomeric molecular weight (HSP10, HSP20-30, HSP40, HSP60, HSP70, HSP90 
and HSP100 families). Some HSP family members (e.g. HSP60 and HSP70) are 
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highly conserved throughout evolution, resulting in immunological cross-recognition 
of certain mammalian and microbial HSP homologues.  
Initial observations that ignited studies on the role of HSPs in autoimmunity 
were made in the mycobacteria-induced adjuvant arthritis model in rats. Generated 
mycobacteria-specific T cell lines were shown to have arthritogenic potential 66 and it 
was later discovered that HSP60 was the antigen recognized by the mycobacteria-
specific T cell lines 67. Further studies followed showing that synovial fluid cells and 
peripheral blood mononuclear cells of chronic inflammatory arthritis patients could 
also respond to mycobacterial HSP60. In contrast, HSP60 responses were absent in 
control subjects 68. Moreover, monoclonal antibodies recognizing mammalian HSP60 
were produced and it was found that HSP60 was expressed in synovial membranes 
of patients with chronic arthritis 69,70. Similar results were found for the HSP family 
members HSP40 and HSP70. Synovial fluid and peripheral blood T cells of RA 
patients could recognize a bacterial variant of HSP40, but healthy subjects or 
disease controls could not 71. In addition, the human homologues of HSP40 and 
HSP70 were found to be overexpressed in the synovial lining of the joints of RA 
patients 72,73.  
Interestingly, numerous experimental animal models and even a few clinical 
trials have shown that treatment with (myco)bacterial HSPs can induce HSP-specific 
anti-inflammatory T cell responses. Experimental autoimmune disease models in 
both rat and mouse showed significantly reduced arthritis severity after prophylactic 
immunization with mycobacterial HSP60 or HSP70 74,75. Although the exact 
mechanism for disease amelioration is still not completely understood, suppression 
of arthritis is likely induced by IL-10 producing Tregs 75-78. One possible explanation 
for the propagation and/or induction of a regulatory phenotype in HSP60/70-specific 
T cells lies in the high homology between the bacterial and mammalian variants of 
the HSP proteins. Even though HSPs are considered immunogenic - microbial 
HSP60, for example, has been known as the so-called ‘common antigen of gram 
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negatives’ already before its molecular definition79 - the highly conserved parts of the 
proteins could induce a tolerogenic response as these can be recognized as self-
antigens by the body’s own immune system80. Moreover, since bacterial HSPs are 
mostly encountered in the tolerising gut or lung mucosa, conserved and thus 
repeatedly encountered HSP antigens are more likely to obtain a regulatory 
phenotype. In addition to conservation and microbial-self cross-recognition, HSP70 
family members are directly involved with antigen processing and consequently, 
HSP70 fragments were found to be one of the most frequent cytosolic MHCII natural 
ligand sources81-83. Presentation of HSP70 peptides may therefore be part of the 
earlier mentioned default tolerant state of the immune system, where MHCII 
presented HSP peptides are part of a continuous and credible target for Tregs. It is, 
however, important to keep in mind that in a dysregulated immune system like seen 
in patients with autoimmune diseases, antigens that would normally induce an anti-
inflammatory immune response, could now potentially induce a pro-inflammatory 
response. 
Since the HSPs used for the previous described experiments are from 
bacterial origin and can potentially induce an unwanted anti-inflammatory response 
towards these bacteria, a safer form of the HSPs is needed. One way to accomplish 
this is to use bacterial HSP-derived peptides that show high homology with the 
mammalian variant. The high homology to the self-antigen will prevent unwanted 
responses towards the bacteria and at the same time ensure cross-reactivity with the 
mammalian HSPs presented in the inflamed joint. Indeed, two of the three clinical 
trials using HSPs as therapy were performed with HSP-derived peptides. A pilot 
phase II trial using a HSP40-derived peptide, dnaJP1; which also contains the 
‘shared epitope’ 84, was tested in juvenile idiopathic arthritis (JIA) patients. After oral 
administration of the dnaJP1, a change from a pro-inflammatory to a tolerogenic T 
cell response to dnaJP1 could be observed 85,86. In a second phase II trial, an 
HSP60-derived peptide, DiaPep277, was used to treat patients with type I diabetes. It 
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was found that DiaPep277 was safe and showed a trend towards a greater 
preservation of beta-cell function as compared to controls 87,88. In a third recent trial, a 
mammalian HSP70 family member, BiP, was tested in RA patients. In this case, 
whole protein was administered intravenously. The results of this phase I/II safety 
trial showed no serious adverse drug reactions. Moreover, at the higher treatment 
doses disease remissions were seen in some cases 89.  
As discussed earlier, one potential disadvantage of using peptides is HLA 
diversity in patients. Consequently, HSP peptides need to either 1) be able to bind 
multiple HLA-DR molecules, including the RA associated HLA-DRB1 *0101, *0401, 
*0404 molecules, or 2) a peptide pool of several HSP peptides able to bind one or 
more of the RA associated HLA-DR molecules needs to be administered. For HSP60 
and HSP70 several pan-DR peptides have been discovered. Kamphuis et al used a 
computer algorithm to identify both self and bacterial HSP60 peptides able to bind a 
number of distinct HLA-DR haplotypes. They found several peptides that were able 
to bind the major RA/JIA-associated HLA-DR molecules and T cells from both JIA 
and RA patients were able to respond to five out of eight peptides 90,91. In addition, de 
Wolf et al showed that an HSP70 peptide, B29, also binds multiple HLA-DR 
molecules. They concluded that more than 80% of human individuals can present 
B29 to their T cells (and among RA patients possibly even more due to high 
presence of HLA-DRB1 *0401). In subsequent cultures they showed that 10 out of 14 
healthy individuals could respond to the peptide 92. The B29 peptide was earlier 
tested in a mouse model of arthritis and it was found that prophylactic intranasal 
administration of B29 could suppress disease. Moreover, CD25+CD4+ T cells from 
B29 immunized mice could decrease disease severity in recipient arthritic mice, 
indicating that B29-specific Tregs are effective in diminishing autoimmune arthritis 83.  
Next to the Treg inducing potential of B29, bone marrow derived dendritic 
cells pulsed with Mycobacterium tuberculosis (Mt) or mouse HSP70 induced IL-10 
14 
 
production in antigen-specific T cells and suppressed arthritis showing that HSP70 
loading of DCs by itself is tolerising93. 
In order to make both tolDC therapy and HSP peptide treatment in 
autoimmune diseases (e.g. RA) as potent as possible, a combination therapy could 
be the solution. Pulsing tolDCs with HSP peptides could 1) solve the autoantigen 
problem and 2) the HSP peptides will be targeted to the HSP-specific T cells by DC 
with stable tolerogenic function, making sure a regulatory response towards the 
antigen is induced.  
 
5. Conclusion 
 
The fundamental problem in autoimmune diseases is the failure of the immune 
system to down-regulate its own potentially dangerous cells leading to destruction of 
tissue expressing the autoantigen. In the case of RA, currently available 
immunosuppressive therapies offer relief but fail to induce long-term physiological 
regulation resulting in medication-free remission. 
As argued here, to restore immune tolerance, autologous tolDCs loaded with 
a HSP-derived peptide antigen could be used. Such a therapy could potentially both 
tolerise arthritogenic T cells and induce disease-suppressive regulatory T cells. 
Targeting the physiological mechanism of re-establishing tolerance for self-antigens 
offers the opportunity to inhibit joint-destroying immune responses long-term.  
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Fig 1. HSP loaded tolerogenic dendritic cell (tolDC) vaccination in Rheumatoid 
arthritis (RA). This figure depicts the potential process that takes place in the 
patient’s joint after injection with HSP loaded tolDC. TolDC produce anti-inflammatory 
cytokines (eg IL-10) and present epitopes of HSP to naive CD4+ T cells. These 
CD4+ T cells differentiate into HSP specific Treg and suppress stressed (HSP 
expressing) cells via immunomodulatory cytokines like IL-10 and TGF-β. 
Furthermore, bystander suppression could lead to suppression of pathogenic Teff 
cells recogizing the unknown auto antigen, thereby inhibiting inflammatory 
symptoms. The presence of self hsp in the synovial fluid of RA patients might favor 
the selection of the generation of Treg and their function. 
 
Table 1: HSPs and peptides associated with therapeutic interventions in chronic 
inflammatory diseases. dnaJP1 and DiaPep277 were tested in phase II clinical trials 
in juvenile RA and diabetes (refs. 85; 87). mB29a is now explored for the loading of 
tolDC in RA (refs. 83; 92). The peptides are based on human Hsp sequences. 
 

HSP Peptide Sequence
HSP70 (HspA9) mB29a VLRVINEPTAAALAY
HSP60 (HspD1) DiaPep277 VLGGGVALLRVIPALDSLTPANED
HSP40 (dnaJB1) dnaJP1 QKRAAYDQYGHAAFE
